CompletedPhase 1

Elacytarabine Mass Balance Study in Healthy Volunteers

United Kingdom6 participantsStarted 2013-02

Plain-language summary

This study is performed to measure the quantity of i.v. applied elacytarabine that leave the body, by which route and how fast.

Age range50 Years – 65 Years

SexMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

✕. Participation in a clinical research study within the previous 3 months
✕. Subjects who are study site employees, or immediate family members of a study site or sponsor employee
✕. Subjects who have previously been enrolled in this study or in any other elacytarabine study
✕. History of any drug or alcohol abuse in the past 2 years

mass balance of elacytarabine after i.v. dosing

Timeframe: Two weeks after administration

NCT IDNCT01783964

SponsorClavis Pharma

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2013-02